Fox R, Arnold DL Bar-Or A, et al. Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study. ECTRIMS 2017, 129.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose